Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size was valued at US$ 1308 million in 2024 and is forecast to a readjusted size of USD 2016 million by 2031 with a CAGR of 6.4% during review period.

Non-alcoholic steatohepatitis (NASH) is a form of liver disease characterized by inflammation and liver cell damage caused by the accumulation of fat in the liver. It is often associated with obesity, insulin resistance, and metabolic syndrome. As there is currently no approved specific therapy for NASH, treatment primarily focuses on managing the underlying risk factors and minimizing liver damage.

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market refers to the market for treatments and diagnostic tools used in the management and detection of NASH, a chronic liver disease characterized by the accumulation of fat in the liver.

The NASH therapeutics market is driven by several factors. Firstly, the rising prevalence of obesity and metabolic disorders, such as diabetes and dyslipidemia, contributes to the increasing incidence of NASH. Lifestyle changes, sedentary habits, and unhealthy diets have led to a global epidemic of NASH, necessitating the development of effective treatment options.

Secondly, the lack of specific pharmacological therapies approved for NASH creates an opportunity for research and development in the market. Currently, treatment options revolve around lifestyle modifications, including weight reduction, dietary changes, exercise, and management of comorbidities. However, there is a growing need for targeted pharmaceutical interventions to address the underlying mechanisms of NASH.

Furthermore, the increasing awareness about the potential progression of NASH to advanced liver diseases such as fibrosis, cirrhosis, and hepatocellular carcinoma drives the demand for NASH therapeutics. Timely diagnosis and treatment of NASH are crucial to prevent disease progression and reduce the burden on healthcare systems.

The NASH diagnostics market is also an important component of the overall market. Accurate diagnosis and staging of NASH are critical for determining appropriate treatment strategies. Diagnostic tools such as blood tests, imaging techniques (ultrasound, magnetic resonance imaging), and liver biopsy help in evaluating liver function, detecting inflammation and fibrosis, and assessing the severity of NASH.

Geographically, North America is a significant market for NASH therapeutics and diagnostics due to the high prevalence of obesity and related metabolic disorders in the region. Europe and Asia-Pacific also show substantial market potential, driven by increasing healthcare awareness, growing patient population, and improving healthcare infrastructure.

Key players in the global NASH therapeutics and diagnostics market include pharmaceutical companies, biotechnology firms, diagnostic test manufacturers, and healthcare providers. These companies are actively engaged in clinical trials, research collaborations, and strategic partnerships to develop novel therapies and diagnostic tools for NASH.

In conclusion, the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is driven by the increasing prevalence of obesity and metabolic disorders, the need for targeted pharmacological interventions, and the importance of early diagnosis and intervention. The market presents opportunities for new treatment options, diagnostic advancements, and partnerships aimed at addressing the rising burden of NASH on public health.

This report is a detailed and comprehensive analysis for global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size and forecasts, in consumption value ($ Million), 2020-2031

Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Allergan plc, Pfizer Inc, Gilead Sciences, Genfit SA, Novartis AG, Intercepts Pharmaceuticals, Cadila Healthcare, Novo Nordisk, Raptor Pharmaceutical Corp, Galmed Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Imaging Techniques

Diagnostic Tests

Biopsy

Others

Market segment by Application

Hospital Pharmacy

Online Channels

Retail Channels

Others

Market segment by players, this report covers

Allergan plc

Pfizer Inc

Gilead Sciences

Genfit SA

Novartis AG

Intercepts Pharmaceuticals

Cadila Healthcare

Novo Nordisk

Raptor Pharmaceutical Corp

Galmed Pharmaceuticals

Madrigal Pharmaceuticals

Viking Therapeutics

Conatus Pharmaceuticals

NGM Biopharmaceuticals

CymaBay Therapeutics

Boehringer Ingelheim

Eli Lilly and Company

Bristol Myers Squibb

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics, with revenue, gross margin, and global market share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics from 2020 to 2025.

Chapter 3, the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics.

Chapter 13, to describe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics research findings and conclusion.